Less Ads, More Data, More Tools Register for FREE

Pin to quick picksGenedrive Regulatory News (GDR)

Share Price Information for Genedrive (GDR)

Share Price is delayed by 15 minutes
Get Live Data
1.325    0.075 (6.00%)
Bid:
1.25
Ask:
1.40
Spread: 0.15 (12.00%)
Market Cap: £21.27m
GDR Live PriceLast checked at - London Stock Exchange

Intraday Genedrive Share Chart

Director/PDMR Shareholding

7 Oct 2013 08:29

RNS Number : 8582P
Epistem Holdings plc
07 October 2013
Β 

ο»Ώ

Β 

Β 

Epistem Holdings Plc ("Epistem" or the "Company")

Β 

Directors' Shareholdings

Β 

Epistem today provides an update regarding the Company's share investment plan, details of which were announced on 13 July 2009.

Β 

As a result of the subscription for Partnership Shares and the award of Matching Shares, the executive Directors each increased their beneficial interests in the Company by 228 ordinary shares of 1.5p each. These shares were acquired on 30th July 2013, 30th August 2013 and 27th September 2013 at prices of 583p, 560p and 383p respectively.

Following these transactions, the current beneficial interests of the executive Directors are set out below:

Β 

Ordinary Shares %

Β 

Matthew Walls 10,600 0.11%

Dr Catherine Booth 984,955 10.17%

Dr Jeffrey Moore 14,280 0.15%

John Rylands 194,853 2.01%

Β 

Β 

Β 

Β 

For further details please contact:

Β 

Epistem Plc

Matthew Walls, CEO +44 161 606 7258

John Rylands, Finance Director +44 161 606 7244

Β 

Peel Hunt LLP

James Steel /Vijay Barathan +44 20 7418 8900

Β 

This information is provided by RNS
The company news service from the London Stock Exchange
Β 
END
Β 
Β 
RDSGRBDGRDGBGXR
Date   Source Headline
1st Oct 202512:31 pmRNSHolding(s) in Company
1st Oct 202512:30 pmRNSHolding(s) in Company
30th Sep 20259:52 amRNSHolding(s) in Company
29th Sep 20255:03 pmRNSHolding(s) in Company
29th Sep 20253:00 pmRNSPublication of Circular and Notice of GM
29th Sep 20257:00 amRNSResult of Retail Offer
24th Sep 20257:00 amRNSCompletion of Placing
23rd Sep 20255:03 pmRNSProposed Retail Offer
23rd Sep 20254:59 pmRNSProposed Placing to raise a minimum of £3 million
23rd Sep 20259:00 amRNSHolding(s) in Company
23rd Sep 20259:00 amRNSHolding(s) in Company
15th Sep 20254:24 pmRNSResult of General Meeting
10th Sep 20254:15 pmRNSHolding(s) in Company
10th Sep 20254:15 pmRNSHolding(s) in Company
29th Aug 202512:00 pmRNSProposed Share Capital Reorganisation & GM
21st Aug 20257:00 amRNSScotland’s Public Health Minister visit
14th Aug 202510:35 amRNSComment re: Share Price Movement
11th Aug 20257:00 amRNSTrading update
30th May 20257:00 amRNSBlock Listing Returns
30th May 20257:00 amRNSCE-certification
13th May 20257:00 amRNSCYP2C19-ID Kit used to support expansion
2nd May 20251:30 pmRNSCYP2C19 ID Kit CE-IVD certification update
2nd Apr 20257:01 amRNSAdditional grant funding under DEVOTE programme
2nd Apr 20257:00 amRNSReceipt of R&D tax credit
1st Apr 20257:00 amRNSResult of RetailBook Offer
27th Mar 20253:30 pmRNSRetailBook Offer
27th Mar 20253:29 pmRNSHalf-year Report
27th Mar 20253:28 pmRNSEquity Fundraise
17th Mar 202511:04 amRNSScottish Government testing programme investment
14th Mar 20257:00 amRNSCYP2C19-ID Kit adopted for routine clinical use
30th Dec 202411:54 amRNSResult of AGM
27th Dec 20247:00 amRNSGenedrive® CYP2C19-ID Kit performance published
20th Dec 202412:16 pmRNSGrant of Options
20th Dec 202412:12 pmRNSDirector/PDMR Shareholding
5th Dec 20243:00 pmRNSPosting of annual report and notice of AGM
29th Nov 20241:00 pmRNSBlock listing returns
29th Nov 20247:00 amRNSFinal Results
22nd Nov 20247:00 amRNSNotice of Results
21st Nov 202411:06 amRNSNIHR and OLS Funding Package
4th Nov 20241:29 pmRNSScottish Health Technology Group publications
21st Oct 20243:22 pmRNSDirector Declaration
15th Aug 202410:39 amRNSDirector/PDMR Shareholding
12th Aug 20247:00 amRNSFirst UK commercial sales of the CYP2C19-ID Kit
6th Aug 20247:00 amRNSDirectorate Change
31st Jul 20247:00 amRNSNICE recommends CYP2C19-ID Kit in final guidance
15th Jul 20247:00 amRNSBreakthrough Device Designation from the U.S. FDA
27th Jun 20249:28 amRNSShort extension to NICE publication date
25th Jun 20247:00 amRNSHolding(s) in Company
24th Jun 202411:13 amRNSHolding(s) in Company
24th Jun 202411:12 amRNSHolding(s) in Company

Due to London Stock Exchange licensing terms, we stipulate that you must be a private investor. We apologise for the inconvenience.

To access our Live RNS you must confirm you are a private investor by using the button below.